| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Lomitapide |
| Brand | Lojuxta® |
| Indication | As an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). |
| Assessment Process | |
| Rapid review commissioned | 09/09/2014 |
| Rapid review completed | 15/09/2014 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.